



06-20-01

Attorney Docket No.: G0694/7002 (JRV)

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	G0694/7002 (JRV)
First Named Inventor or Application Identifier	
Richard S. Blumberg	U.S. PTO JC97-88196
Express Mail Label No.	EL844512075US
Date of Deposit	June 19, 2001



**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents

1.  Fee Transmittal Form  
*(Submit an original, and a duplicate for fee processing)*
2.  Applicant claims small entity status.  
See 37 CFR 1.27.  
 Small Entity Statement(s)  
 Statement filed in prior application, Status still proper and desired.
3.  Specification [Total pages 40]  
 33 - pages description  
 1 - pages abstract  
 6 - pages claims      56 - Total claims
4.  Drawing(s) (35 USC 113) [Total sheets 9]  
 Informal     Formal [Total drawings 8]
5.  Oath or Declaration [Total pages 2]  
 a.  Newly executed (original or copy)  
 b.  Copy from a prior application (37 CFR 1.63(d))  
*(for continuation/divisional with Box 19 completed)*  
*[Note Box 6 below]*  
 i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6.  Incorporation by Reference  
*(usable if Box 5b is checked)*  
 The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein. **See 19.**
7.  Application Data Sheet, See 37 CFR 1.76

ADDRESS TO:	Box Patent Application Commissioner for Patents Washington, DC 20231
8. <input type="checkbox"/> CD-ROM or CD-R, in duplicate, large table or Computer Program (Appendix)	9. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Computer Readable Form - See OTHER</li> <li>b. <input checked="" type="checkbox"/> Specification Sequence Listing on:               <ol style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li> <li>ii. <input checked="" type="checkbox"/> paper (identical to computer copy)</li> </ol> </li> <li>c. <input checked="" type="checkbox"/> Statement verifying identity of above</li> </ol>
<b>ACCOMPANYING APPLICATION PARTS</b>	
10. <input type="checkbox"/> Assignment Papers/cover sheet & documents(s)	11. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney
12. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i>	13. <input checked="" type="checkbox"/> Information Disclosure Statement PTO-1449 <input checked="" type="checkbox"/> Copies of IDS Citations (1)
14. <input checked="" type="checkbox"/> Preliminary Amendment	15. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>
16. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>	17. <input type="checkbox"/> Request and Certification Under 35 U.S.C. <b><u>§122(b)(2)(B)(ii)</u></b> <i>(if foreign priority is claimed)</i>
18. <input checked="" type="checkbox"/> Other: <u>Copy of face of earlier filed Computer Readable Form (CRF), and Letter Requesting Use of Computer Readable Form From Another Application</u>	

19. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in the body of the application, or a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:

Divisional of prior application No. :09/294,504, filed on April 15, 1999, entitled *T CELL INHIBITORY RECEPTOR COMPOSITIONS AND USES THEREOF*, now Pending; and which claimed priority from U.S. provisional patent application serial number 60/081,895.

*Prior application information:*

*Examiner A. DeCloux*

*Group Art Unit: 1644*

For CONTINUATION OR DIVISIONAL APPS ONLY: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

20. CORRESPONDENCE ADDRESS

*Correspondence address below*

**CUSTOMER NUMBER:**



**23628**

21. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED

NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	<i>John R. Van Amsterdam</i>
DATE	June 19, 2001

Inventor or Identifier: Richard S. Blumberg

Serial No: Not yet assigned

Filed: Herewith

CHECK BOX, if applicable:

For: T CELL INHIBITORY RECEPTOR COMPOSITIONS AND  
USES THEREOF DUPLICATE

## Fee Calculation Sheet

CLAIMS	FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEES
	TOTAL CLAIMS (37 CFR 1.16(c))	24-20=	4 x	\$18	= \$ 72.00
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	2-3=	0 x	\$80	= \$ 0.00
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR 1.16(d)) +			\$260	= \$
				BASIC FEE (37 CFR 1.16(a))	\$ 710.00
				Total of above Calculations =	\$ 782.00
	Reduction by 50% for filing by small entity (Note 37 CFR 1.9, 1.27, 1.28).				\$ -391.00
	Assignment Recordation Fee (if any)				\$
	Other Fees (if any).				\$
				TOTAL =	\$ 391.00

1. A check in the amount of \$391.00 is enclosed.

## General Authorization to Charge Deposit Account and General Request for Extension of Time

2. a.  If the filing of any paper in this application necessitates the payment of a fee under 37 CFR §§  1.16  1.17 or  1.18, and the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.
- b.  The applicant hereby revokes any prior authorization to charge a fee due under 37 CFR §§  1.16  1.17 or  1.18.
3. If the filing of any paper in this application necessitates an extension of time under 37 CFR § 1.136(a), the applicant hereby requests such extension of time. If the fee due is in an amount different from any enclosed check or if no check is enclosed, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 23/2825.

John R. Van Amsterdam, Reg. No. 40,212  
 Wolf, Greenfield & Sacks, P.C.  
 600 Atlantic Avenue  
 Boston, MA 02210-2211  
 (617) 720-3500  
 Attorneys of Record

Docket No. G0694/7002 (JRV)  
 Date: June 19, 2001

Express Mail Label No.  
**EL844512075US**  
Date of Deposit: **06-19-01**

ATTORNEY'S DOCKET NO. G0694/7002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard S. Blumberg  
Serial No: Unknown  
Filed: Herewith  
For: T Cell Inhibitory Receptor Compositions and Uses Thereof

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**STATEMENT PURSUANT TO 37 CFR 1.821(f)**

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith a paper copy of the Sequence Listing and request to use a computer readable diskette from a prior application. Applicant's attorney states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information and contain no new matter.

Respectfully submitted,

  
John R. Van Amsterdam  
Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
(617) 720-3500

Docket No.: G0694/7002

Dated: June 19, 2001

**Xndd**

ATTORNEY'S DOCKET NO. G0694/7002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard S. Blumberg  
Serial No: Unknown  
Filed: Herewith  
For: T Cell Inhibitory Receptor Compositions and Uses Thereof

Box Patent Application  
Commissioner for Patents  
Washington, D.C. 20231

**LETTER REQUESTING USE OF COMPUTER READABLE FORM  
FROM ANOTHER APPLICATION**

Sir:

In accordance with 37 C.F.R. §1.821(e) regarding submission of a computer readable form of nucleotide and/or amino acid sequence disclosures in a new application which corresponds to the sequence information from another application already on file at the United States Patent and Trademark Office, Applicants request use of the previously filed computer readable form. The Sequence Listing enclosed herewith is identical to that filed on April 15, 1999 in a previous application, Serial No. 09/293,504, which is the parent application of the divisional application filed herewith. In accordance with 37 C.F.R. 1.821(e), please use the last-filed computer readable form filed in application Serial No. 09/293,504 as the computer readable form for the instant application. It is understood that the U.S. Patent and Trademark Office will make the necessary change in application number, docket number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing for the instant application is included herewith. Applicants' attorney states that the paper copy filed herewith and the computer readable form filed in application Serial No. 09/293,504 are identical and contain no new matter.

The computer readable form was filed as a 3½ inch diskette containing the file *bgpu.txt* in ASCII text format. A copy of the face of the computer disk is enclosed.

Respectfully submitted,



John R. Van Amsterdam  
Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
(617) 720-3500

Docket No.: G0694/7002

Dated: June 19, 2001

**Xndd**